MERCK, Sharp & Dohme (MSD) Malaysia recently announced the approval of an oral tablet combining a dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin, and metformin for the treatment of type 2 diabetes in Malaysia.
The drug, approved by the Drug Control Authority of Malaysia in May 2008, is indicated as initial therapy to improve blood sugar control in patients with type 2 diabetes who are not adequately controlled with diet and exercise alone.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!